Clinical Trials Browser

Has announcements × Neuroblastoma × 1 year × Clear all

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT03363373 2026-02-19

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Phase 2 Recruiting

122 enrolled 3 FDA

CNS

Neuroblastoma

NCT01757626 2026-01-07

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Phase 1/2 Active not recruiting

186 enrolled 3 FDA

CNS

Neuroblastoma

Clinical Trials

STARTRK-NG

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma